• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在纤溶酶原激活物水平上人类血浆中纤维蛋白溶解的启动与调节。

Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level.

作者信息

Wun T C, Capuano A

出版信息

Blood. 1987 May;69(5):1354-62.

PMID:3105619
Abstract

The initiation and regulation of fibrinolysis has been studied by reconstitution of fibrinolytic activity in human plasma in vitro. Depletion of tissue plasminogen activator (tPA) antigen by immunoadsorption of human plasma with anti-tPA Ig Sepharose 4B leads to total loss of spontaneous fibrinolytic activity determined by lysis of a thrombin-induced clot. Addition of physiological concentrations of purified tPA to tPA-depleted plasma restores fibrinolytic activity as a function of the length of time between tPA addition and clotting. Addition of free tPA to tPA-depleted plasma followed by immediate clotting results in a high rate of fibrinolysis. In contrast, when free tPA is allowed to incubate in plasma for 10 to 60 minutes prior to clot formation, the fibrinolytic activity of tPA is gradually lost. The loss of tPA-induced fibrinolytic activity in unclotted plasma is accompanied by decreased partitioning of tPA antigen into fibrin after clotting and is kinetically correlated with the formation of a 100 kilodalton (kDa) tPA complex as demonstrated by SDS-gel electrophoresis and fibrin-agar zymography. These results suggest that free tPA is susceptible to complexation by the plasma inhibitor in the absence of a clot. Fibrin formation renders tPA relatively inaccessible to inhibition. The tPA antigen isolated from stored plasma consists mainly of 100 kDa activity in SDS-gel electrophoresis and zymography, indicating that the tPA complex is resistant to dissociation by SDS. Upon rezymography of the sliced gel, only a 60 kDa tPA activity is found, suggesting that the activity at 100 kDa is at least partly due to free tPA dissociated from the complex during the first zymography. Conversion of tPA complex to enzymatically active free tPA also occurs with brief SDS exposure followed by incubation in the presence of excess Triton X-100 or by hydroxylamine treatment. These results reconcile the apparent discrepancy of the 100 kDA inhibitor-tPA complex manifesting plasminogen activation activity during zymography. The plasma tPA-inhibitor complex is precipitated strongly by antisera against plasminogen activator inhibitors (PAIs) of human Hep G2 hepatoma and HT-1080 fibrosarcoma cells and weakly by antiserum against bovine aortic endothelial cell PAI but not by antiserum against a placental PAI (PAI-2) suggesting that the plasma inhibitor is immunologically related to Hep G2, HT-1080 and possibly endothedial cell PAIs. Based on the above findings, a simple model for the initiation and regulation of plasma fibrinolysis at the PA level has been formulated.

摘要

通过在体外重组人血浆中的纤溶活性,对纤溶作用的启动和调节进行了研究。用抗tPA Ig Sepharose 4B免疫吸附人血浆,使组织纤溶酶原激活物(tPA)抗原耗竭,导致通过凝血酶诱导的凝块溶解所测定的自发纤溶活性完全丧失。向tPA耗竭的血浆中添加生理浓度的纯化tPA,可恢复纤溶活性,其是添加tPA与凝血之间时间长度的函数。向tPA耗竭的血浆中添加游离tPA后立即凝血,会导致高纤溶速率。相反,当在凝块形成前让游离tPA在血浆中孵育10至60分钟时,tPA的纤溶活性会逐渐丧失。未凝血浆中tPA诱导的纤溶活性丧失伴随着凝血后tPA抗原向纤维蛋白中的分配减少,并且在动力学上与100千道尔顿(kDa)tPA复合物的形成相关,如SDS-凝胶电泳和纤维蛋白-琼脂酶谱法所示。这些结果表明,在没有凝块的情况下,游离tPA易受血浆抑制剂的复合作用影响。纤维蛋白的形成使tPA相对不易被抑制。从储存血浆中分离的tPA抗原在SDS-凝胶电泳和酶谱法中主要由100 kDa活性组成,表明tPA复合物对SDS解离具有抗性。对切片凝胶进行再酶谱分析时,仅发现60 kDa的tPA活性,表明100 kDa处的活性至少部分归因于在第一次酶谱分析期间从复合物中解离的游离tPA。在短暂暴露于SDS后,接着在过量Triton X-100存在下孵育或通过羟胺处理,也会发生tPA复合物向具有酶活性的游离tPA的转化。这些结果解释了在酶谱分析期间100 kDA抑制剂-tPA复合物表现出纤溶酶原激活活性这一明显差异。血浆tPA-抑制剂复合物被针对人Hep G2肝癌细胞和HT-1080纤维肉瘤细胞的纤溶酶原激活物抑制剂(PAIs)的抗血清强烈沉淀,被针对牛主动脉内皮细胞PAI的抗血清弱沉淀,但不被针对胎盘PAI(PAI- 2)的抗血清沉淀,这表明血浆抑制剂在免疫上与Hep G2、HT-1080以及可能的内皮细胞PAIs相关。基于上述发现,已构建了一个在PA水平上血浆纤溶作用启动和调节的简单模型。

相似文献

1
Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level.在纤溶酶原激活物水平上人类血浆中纤维蛋白溶解的启动与调节。
Blood. 1987 May;69(5):1354-62.
2
Immunoradiometric quantitation of tissue plasminogen activator-related antigen in human plasma: crypticity phenomenon and relationship to plasma fibrinolysis.
Blood. 1987 May;69(5):1348-53.
3
Clot lysis mediated by cultured human microvascular endothelial cells.培养的人微血管内皮细胞介导的血栓溶解
Thromb Haemost. 1988 Dec 22;60(3):463-7.
4
Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor.蛋白C依赖性血栓溶解机制:纤溶酶原激活物抑制剂的作用
Blood. 1986 Dec;68(6):1218-23.
5
TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.TM5275 延长了分泌型组织型纤溶酶原激活物的保留时间,并增强了血管内皮细胞的纤溶作用。
Thromb Res. 2013 Jul;132(1):100-5. doi: 10.1016/j.thromres.2013.04.003. Epub 2013 Apr 20.
6
Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.经尿道前列腺切除术患者血液纤溶与术中或术后即刻失血之间缺乏相关性。
Br J Urol. 1997 Jul;80(1):105-10. doi: 10.1046/j.1464-410x.1997.00251.x.
7
Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.认识到纤溶酶原激活物抑制剂1是纤维蛋白溶解的主要调节因子。
Curr Drug Targets. 2019;20(16):1695-1701. doi: 10.2174/1389450120666190715102510.
8
Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.使用固定化无水尿激酶亲和纯化活性纤溶酶原激活物抑制剂-1(PAI-1)。证明玻连蛋白对PAI-1的结合、稳定和激活作用。
J Biol Chem. 1989 May 15;264(14):7862-8.
9
Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.高度稳定的1型纤溶酶原激活物抑制剂(VLHL PAI-1)可保护纤维蛋白凝块免受组织纤溶酶原激活物介导的纤维蛋白溶解作用。
Int J Mol Med. 2007 Nov;20(5):683-7.
10
Diurnal variation of the fibrinolytic system.纤维蛋白溶解系统的昼夜变化。
Thromb Haemost. 1988 Jun 16;59(3):495-9.

引用本文的文献

1
Plasma tissue-type plasminogen activator is associated with lipoprotein(a) and clinical outcomes in hospitalized patients with COVID-19.血浆组织型纤溶酶原激活剂与COVID-19住院患者的脂蛋白(a)及临床结局相关。
Res Pract Thromb Haemost. 2023 Aug 8;7(6):102164. doi: 10.1016/j.rpth.2023.102164. eCollection 2023 Aug.
2
Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.定量纤溶的检测方法:优缺点。国际血栓与止血学会科学和标准化委员会关于纤溶的通讯。
J Thromb Haemost. 2023 Apr;21(4):1043-1054. doi: 10.1016/j.jtha.2023.01.008. Epub 2023 Jan 14.
3
Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity.
交互作用的肝 PAI-1/tPA 基因调控途径影响肥胖患者纤溶活性受损的严重程度。
J Clin Invest. 2020 Aug 3;130(8):4348-4359. doi: 10.1172/JCI135919.
4
An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1.肝细胞中的 ATF6-tPA 途径有助于全身纤维蛋白溶解,并受 DACH1 抑制。
Blood. 2019 Feb 14;133(7):743-753. doi: 10.1182/blood-2018-07-864843. Epub 2018 Dec 1.
5
Endothelial fibrinolytic response onto an evolving matrix of fibrin.内皮细胞对正在形成的纤维蛋白基质的纤溶反应。
BMC Hematol. 2016 Apr 14;16:9. doi: 10.1186/s12878-016-0048-6. eCollection 2016.
6
An endothelial storage granule for tissue-type plasminogen activator.
J Cell Biol. 1997 Oct 6;139(1):245-56. doi: 10.1083/jcb.139.1.245.
7
Trends and future developments in the pharmacological treatment of acute ischaemic stroke.急性缺血性脑卒中药物治疗的趋势与未来发展
Drugs. 1997 Jul;54(1):9-38. doi: 10.2165/00003495-199754010-00002.
8
Polarized secretion of tissue-plasminogen activator in cultured thyroid cells.
In Vitro Cell Dev Biol. 1993 Feb;29A(2):161-4. doi: 10.1007/BF02630948.
9
The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression.在人脐静脉内皮细胞培养物中添加内皮细胞生长因子和肝素可降低纤溶酶原激活物抑制剂-1的表达。
J Clin Invest. 1988 Aug;82(2):579-85. doi: 10.1172/JCI113635.
10
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.与纤维蛋白结合的1型纤溶酶原激活物抑制剂(PAI-1)与组织型纤溶酶原激活物(t-PA)或尿激酶型纤溶酶原激活物(u-PA)之间的相互作用。t-PA的指状结构域和kringle-2结构域介导t-PA/PAI-1复合物与纤维蛋白的结合。
J Clin Invest. 1989 Aug;84(2):647-55. doi: 10.1172/JCI114211.